US clearance for Cook's Evolution oesophageal stent
This article was originally published in Clinica
Cook Medical has received US FDA 510(k) clearance for its Evolution controlled-release oesophageal stent system for oesophageal cancer. The Bloomington, Indiana-based firm said it was "the first and only stent delivery system that enables deployment and recapturability of the stent with unprecedented precision". As the stent can be placed precisely the first time, this may reduce the need for repeat procedures. It has a retractable delivery system and a "point-of-no-return" indicator which alerts the physician when recapture is no longer available. It is also the only oesophageal stent with an internal and external silicone coating, Cook claims, which resists tumour ingrowth into the stent and enhances patients' ability to swallow food normally.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.